BAKU, Azerbaijan, August 28. The production
volume of Kazakhstan's pharmaceutical enterprises has increased by
37% over the past three years, reaching 191 billion tenge (about
$416 million) in 2025.
This was announced in a statement by the press service of the
Kazakh Government.
According to the information, the positive trend has continued
in 2026, with the output of medicines and medical products reaching
126.6 billion tenge ($275 million) in the first half of the year,
nearly 30% higher than in the same period of 2025.
"Today, 209 manufacturers of pharmaceutical and medical products
operate in the country, including 43 enterprises producing
medicines. As of August 2026, the share of domestic products in
physical terms reached 40.3%," the statement said.
Kazakh companies have registered 2,994 types of medicines and
medical products. The range of locally produced products is also
expanding. It includes antibacterial, cardiovascular,
pain-relieving and anti-inflammatory medicines, as well as drugs
for treating diseases of the central nervous system and other
conditions.
Meanwhile, Kazakhstan is developing a long-term procurement
mechanism. As of early 2026, 83 contracts with 31 domestic
manufacturers were in effect for the supply of 2,022 types of
products.
According to the government, the mechanism provides
manufacturers with more predictable demand, allowing them to plan
production capacity, expand operations, and introduce new
medicines. Medicines in Kazakhstan are manufactured in accordance
with Good Manufacturing Practice (GMP) standards.
